Contact
    Start Publications Development and evaluation of polymeric micelle containing ...
    ←  Publication Finder
    Attension

    Development and evaluation of polymeric micelle containing tablet formulation for poorly water-soluble drug: tamoxifen citrate

    Year: 2020

    Journal: Drug Dev. Ind. Pharm., Volume 46, OCT 2, page 1695–1704

    Authors: Ozturk-Atar, Kivilcim; Kaplan, Meryem; Calis, Sema

    Keywords: Polymeric micelle; Pluronic (R) F68; tamoxifen citrate; breast cancer; poor solubility; tablet; triblock copolymer

    Poor aqueous solubility is one of the key reasons for slow dissolution rate and poor intestinal absorption and finally that causes low therapeutic efficacy of many existing drugs. Tamoxifen citrate (TMX) (BCS Class II drug) with low water solubility has poor oral bioavailability in the range of 20%-30%, therefore, high doses are required for treatment with TMX. Self-assemblage of amphiphilic polymers leads to the formation of polymeric micelles which makes them unique nano-carriers with excellent biocompatibility, low toxicity, enhanced blood circulation time, and solubilization of poorly water-soluble drugs. In this study poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) triblock copolymer, which has been approved by FDA for oral application was used to benefit its micellar solubilization effect. Self-assembled micelles were prepared for the delivery of TMX and this way TMX solubility was increased approximately 60 times. TMX-treated cells showed 38.06 +/- 1.5% viability at 50 mu M concentration for 24 h; 66.71 +/- 11.6% viability at 25 mu M concentration for 48 h, at the same conditions TMX-loaded micelles exhibited 24.994 +/- 0.25% and 43.36 +/- 4.37% cell viability, respectively (p < 0.05). These results showed that the encapsulation of TMX into PEG-PPG-PEG micelles facilitated the cellular uptake, which led to an increased cytotoxicity in MCF-7 cancer cells. Tablet formulation containing lyophilized TMX-loaded micelles was showed an improved dissolution than commercial TMX tablet (Tamoxifen (R) TEVA). It can be reasonably expected that the obtained drug dissolution rate and increased cytotoxicity to tumor cells will result in an increase of TMX bioavailability and tolerability associated with an important dose reduction and decreased side effects.
    View publication